NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO - Get Free Report) has been assigned a consensus rating of

Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, whi

Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript

Agios Pharmaceuticals NASDAQ: AGIO reported second-quarter 2026 mitapivat net revenue of $44.7 milli

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.69 per share versus the Zacks Cons

Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second q

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 result

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely

Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) stock is trading lower after the update on the sickle cell

US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading

Agios ​Pharmaceuticals said on Tuesday it ‌will stop development of its sickle cell disease treatmen

Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine,

Agios stock surged after FDA granted priority review for mitapivat in sickle cell disease. Mitapivat

Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sick

Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading v

The company took a major step toward an accelerated approval of mitapivat in sickle cell disease tod

US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earni

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen

U.S. stock futures slightly lower. UiPath joins S&P Midcap 400, Agios receives FDA approval, Can

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earning

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly ear

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnin

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnin

  Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for

  On Tuesday, 951 companies hit new 52-week lows.

  During Monday's trading, 1214 companies set new 52-week lows.

  On Wednesday, 215 companies set new 52-week lows.

  On Tuesday, 540 companies set new 52-week lows.

  Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report